|
IQVIA™ Real-World Insights Bibliography
| Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study |
| Author(s): Avraham Karasik (1), Stefanie Lanzinger (2,3), Elise Chia-Hui Tan (4), Daisuke Yabe (5,6,7 8), Dae Jung Kim (9), Wayne H-H Sheu (10), Cheli Melzer-Cohen (1), Reinhard W. Holl (2), Kyoung-Hwa Ha (9), Kamlesh Khunti (11), Francesco Zaccardi (11), Anuradhaa Subramanian (12), Krishnarajah Nirantharakumar (12,13,14), Thomas Nyström (15), Leo Niskanen (16), Majken Linnemann Jensen (17), Fabian Hoti (18), Riho Klement (19), Anouk Déruaz-Luyet (20), Moe H.Kyaw (21), Lisette Koeneman (22), Dorte Vistisen (23, 24) Bendix Carstensen (23), Sigrun Halvorsen (25), Gisle Langslet (26), Soulmaz Fazeli Farsani (20), Elisabetta Patorno (27), Júlio Núñez (28), EMPRISE Europe and Asia Study Group
|
| Affiliations(s): "1
Maccabi Institute for Research and Innovation Center, Tel Aviv University, Tel Aviv, Israel
2
Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany
3
German Centre for Diabetes Research (DZD), München-Neuherberg, Germany
4
Department of Health Service Administration, China Medical University, Taichung, Taiwan
5
Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan
6
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
7
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
8
Preemptive Food Research Center, Gifu University Institute for Advanced Study, Gifu, Japan
9
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
10
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
11
Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK
12
Institute of Applied Health Research, University of Birmingham, Birmingham, UK
13
Midlands Health Data Research UK, Birmingham, UK
14
DEMAND Hub, University of Birmingham, Birmingham, UK
15
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sweden
16
Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti Finland and University of Eastern Finland, Kuopio, Finland
17
IQVIA Solutions Denmark A/S, Copenhagen, Denmark
18
IQVIA, Espoo, Finland
19
IQVIA, Tartu, Estonia
20
Boehringer Ingelheim International GmbH, Ingelheim, Germany
21
Boehringer Ingelheim International GmbH, US
22
Lilly Deutschland GmbH, Bad Homburg, Germany
23
Steno Diabetes Center Copenhagen, Herlev, Denmark
24
Department of Public Health, University of Copenhagen, Copenhagen, Denmark
25
Department of Cardiology, Oslo University Hospital Ullevål, and University of Oslo, Oslo, Norway
26
Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway
27
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
28
Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain" |
Publication(s): "Diabetes & Metabolism. 2023 Jan; 101418; ISSN 1262-3636
Virtual Conference: American Diabetes Association, 25-29 June 2021 and EASD 27 September -01 October"
|
| Document Type(s): Article, |
| Countries: Denmark, Finland, Germany, Norway, Spain, Sweden, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, |
|
 |
| |
| |
| Empagliflozin is Associated with Lower Risk of Cardiovascular Events and All-Cause Mortality in Routine Care in East Asia: Results from the EMPRISE Study
|
| Author(s): Dae Jung Kim (1), Wayne H-H Sheu (2), Wook-Jin Chung (3), Daisuke Yabe (4-7), Kyoung Hwa Ha (1), Masaomi Nangaku (8), Elise Chia-Hui Tan (9), Koichi Node (10), Atsutaka Yasui (11), Weiyu Lei (12), Sunwoo Lee (13), Laura Saarelainen (14), Anouk Deruaz-Luyet (15), Moe H. Kyaw (16) and Yutaka Seino (4,17), EMPRISE East Asia Study Group
|
| Affiliations(s): "1
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
2
Division of Endocrinology and Metabolism, Taipei Veterans General Hospital, Taipei, Taiwan
3
Department of Cardiovascular Medicine, Gachon University Gil Medical Center, Incheon, South Korea
4
Kansai Electric Power Medical Research Institute, Kobe, Japan
5
Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan
6
Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
7
Division of Metabolism and Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
8
Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo, Japan
9
National Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan, and Institute of Hospital and Healthcare Administration, National Yang-Ming University, Taipei, Taiwan
10
Department of Cardiovascular Medicine, Saga University, Saga, Japan
11
Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan
12
Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan
13
Boehringer Ingelheim Korea Ltd, Seoul, Korea
14
IQVIA, Espoo, Finland
15
Boehringer Ingelheim International GmbH, Ingelheim, Germany
16
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
17
Kansai Electric Power Hospital, Osaka, Japan
" |
Publication(s): "JDI journal
Virtual Conference: ACC, May 2021"
|
| Document Type(s): Article, |
| Countries: Japan, Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes, Drug safety, Drug Utlization Study,
2023 |
|
L:
A: |
English
Clinical setting: hospital, Clinical setting: Primary care, Retrospective cohort analysis, |
|
|
| |
| |
| Hypercholesterolaemia control in Spain: The same situation with different regional realities
|
| Author(s): Juan Pedro-Botet, Núria Plana, José María Mostaza, Juan José Gómez-Doblas, María Rosa Fernández Olmo, Carlos Escobar Cervantes, José Luis Díaz-Díaz, Raquel Campuzano Ruiz, Pedro Valdivielso, Juan Cosín-Sales
|
| Affiliations(s): Unidad de Lípidos y Riesgo Vascular, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España
|
Publication(s): Clinica e investigacion en arteriosclerosis: publicacion oficial de la Sociedad Espanola de Arteriosclerosis, S0214-9168(23)00027-X. 27 Apr. 2023, doi:10.1016/j.arteri.2023.04.001
|
| Document Type(s): Abstract, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2023 |
|
L:
A: |
Spanish
Clinical setting: Primary care, Public Health, Quality of life, Survey research, |
|
|
| |
| |
| Real-world clinical practice of pulmonary arterial hypertension in Japan: Insights from a large administrative database |
| Author(s): Junichi Omura 1, Kazuki Kitahara 1, Masashi Takano 1, Koki Idehara 2, Seok-Won Kim 2 (rwesheorj 2) |
| Affiliations(s): 1) Medical Affairs Janssen Pharmaceutical K. K. Tokyo Japan
2) RWES/HEOR IQVIA Solutions Japan K. K. Tokyo Japan |
Publication(s): Pulmonary Circulation
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2023 |
|
L:
A: |
English
Database Study, Retrospective cohort analysis, |
|
|
| |
| |
| Patient and therapeutic profiles of pulmonary hypertension in chronic lung diseases in Japan: a cohort study using a claims database |
| Author(s): Kazuki Kitahara 1, Junichi Omura 2, Shingo Wada 3, Seok-Won Kim 3 (rwesheorj 3) |
| Affiliations(s): 1) Medical Affairs, Janssen Pharmaceutical K.K., 3-5-2 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan. kkitahar@its.jnj.com
2) Medical Affairs, Janssen Pharmaceutical K.K., 3-5-2 Nishikanda, Chiyoda-ku, Tokyo, 101-0065, Japan
3) Real World Evidence Solutions, IQVIA Solutions Japan K.K., 4-10-18 Takanawa, Minato-ku, Tokyo, 108-0074, Japan |
Publication(s): Pulmonary Therapy
|
| Document Type(s): Article, Online article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Respiratory disease,
2023 |
|
L:
A: |
English
Database Study, Retrospective cohort analysis, |
|
|
| |
| |
| Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction |
| Author(s): Hiroyuki Tsutsui 1 2, Hiroyuki Sakamaki 3, Shin-Ichi Momomura 4, Yasushi Sakata 5, Yutaro Kotobuki 6, Stephan Linden 7, Koki Idehara 8, Daisuke Nitta 6 (rwesheorj 8) |
| Affiliations(s): 1) School of Medicine and Graduate School, International University of Health and Welfare, Tokyo, Japan
2) Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
3) Kanagawa University of Human Services, School of Health Innovation, Kawasaki, Japan
4) Saitama Citizens Medical Centre, Saitama, Japan
5) Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
6) Medicine Division, Nippon Boehringer Ingelheim Co., Ltd., Shinagawa, Tokyo, Japan
7) Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
8) Real World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan |
Publication(s): ESC Heart Failure
|
| Document Type(s): Article, Online article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2023 |
|
L:
A: |
English
Cost analysis, |
|
|
| |
| |
| Cost-effectiveness of vonoprazan compared with proton pump Inhibitors in patients taking low-dose aspirin for secondary prevention of cardiovascular events in Japan |
| Author(s): Masanobu Ishii 1, Takashi Kawai 2, Kenichi Tsujita 3*, Ataru Igarashi 4, Manabu Suzuki 5, Hisato Deguchi 5, Jovelle Fernandez 5 (rwesheorj A) |
| Affiliations(s): 1) Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan
2) Department of Gastroenterological Endoscopy, Tokyo Medical University, Japan
3) Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan
4) Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
5) Japan Medical Office, Takeda Pharmaceutical Company Limited, Japan |
Publication(s): Circulation Journal
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2022 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension |
| Author(s): Allan Lawrie1,2|Neil Hamilton3|Steven Wood2,4|Fernando Exposto5|Ruvimbo Muzwidzwa5|Louise Raiteri5|Amélie Beaudet6|Audrey Muller6|Rafael Sauter6|Nadia Pillai6|David G. Kiel |
| Affiliations(s): 1National Heart and Lung Institute,Imperial College London, London, UK2Insigneo Institute for Inâ€Silico Medicine,University of Sheffield, Sheffield, UK3Sheffield Pulmonary Vascular DiseaseUnit, Sheffield Teaching Hospitals NHSFoundation Trust, Royal HallamshireHospital, Sheffield, UK4Scientific Computing, Sheffield TeachingHospitals NHS Foundation Trust, RoyalHallamshire Hospital, Sheffield, UK5IQVIA, London, UK6Actelion Pharmaceuticals Ltd.,Allschwil, Switzerland7Department of Infection, Immunity andCardiovascular Disease, University ofSheffield, Sheffield, UK |
Publication(s): Pulmonary Circulation. 2022;12:e12136.wileyonlinelibrary.com/journal/pul2|1of10https://doi.org/10.1002/pul2.12136
|
| Document Type(s): Article, |
| Countries: Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Respiratory disease,
2022 |
|
L:
A: |
English
Observational study, Retrospective cohort analysis, |
|
|
| |
| |
| Thrombotic and cardiovascular events and treatment patterns among patients hospitalized with COVID-19 in Japan: an analysis of a nationwide medical claims database |
| Author(s): Naoki Terasaka 1*, Yukako Matsuo 2, Hirohide Kataoka 2, Yasuhiko Miyata 2, Yoshio Anazawa 2 (rwesheorj A) |
| Affiliations(s): 1) Medical Department, Bristol Myers Squibb K.K., Tokyo, Japan
2) Medical Department, Bristol Myers Squibb K.K., Tokyo, Japan |
Publication(s): Cardiology and Therapy
|
| Document Type(s): Article, |
| Countries: Japan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, COVID-19,
2022 |
|
L:
A: |
English
Database Study, |
|
|
| |
| |
| Healthcare resource utilization and quality of life in patients with sarcoidosis-associated pulmonary hypertension
|
| Author(s): Allan Lawrie 1 2, Neil Hamilton 3, Steven Wood 2 4, Fernando Exposto 5, Ruvimbo Muzwidzwa 5, Louise Raiteri 5, Amélie Beaudet 6, Audrey Muller 6, Rafael Sauter 6, Nadia Pillai 6, David G Kiely |
| Affiliations(s): National Heart and Lung Institute, Imperial College London London UK.
2Insigneo Institute for In-Silico Medicine University of Sheffield Sheffield UK.
3Sheffield Pulmonary Vascular Disease Unit Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital Sheffield UK.
4Scientific Computing, Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital Sheffield UK.
5IQVIA London UK.
6Actelion Pharmaceuticals Ltd. Allschwil Switzerland.
7Department of Infection, Immunity and Cardiovascular Disease University of Sheffield Sheffield UK. |
Publication(s): Pulm Circ. 2022 Oct; 12(4): e12136.
Published online 2022 Sep 30. doi: 10.1002/pul2.12136
|
| Document Type(s): Article, |
| Countries: England, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2022 |
|
L:
A: |
English
Observational study, Retrospective cohort analysis, |
|
|
| |
| |
 1 of 54 
|
|
